History
August 15, 2012 | Established; Taka-Aki Sato appointed as President and CEO |
---|---|
August 15, 2012 | Certified as a spin-off venture of the University of Tsukuba |
January 2017 | University of Tsukuba establishes “Research and Development Center for Precision Medicine” Taka-aki Sato serves as Director |
October 2017 | Next-Generation Sequencing service launch |
October 2019 | Registered as a Clinical Laboratory; begins offering Precision-Exome Testing in collaboration with Keio University Hospital and other institutions. |
January 2020 | Capital and business alliance formed with ITOCHU Corporation |
March 2020 | Capital and business alliance formed with Shimadzu Corporation |
September 2020 | Metabolite analysis service Launch |
January 2021 | Genome information value exchange service patent registration (Patent No. 6980240) |
March 2021 | Genomic screening starts in collaboration with the University of Tsukuba Hospital and others |
June 2022 | Long-read sequencing service launched |
March 2023 | Series A funding |
September 2023 | Methylation analysis service launched |
February 2024 | Special analysis service launch |
May 2024 | Launched genetic expression testing in collaboration with Ginza Clinic. |
March 2025 | Series B funding |
July 2025 | Extended series B funding round |